This study is for adults with a skin condition called Cutaneous Lupus Erythematosus (CLE). CLE is a type of lupus that affects the skin. Some participants might also have Systemic Lupus Erythematosus (SLE), which affects the whole body. The study aims to see if a drug called litifilimab can help improve CLE symptoms. Researchers want to find out if litifilimab can reduce skin redness and disease activity. Participants will receive injections every 4 weeks. The study has two parts: the first 24 weeks where participants receive either the drug or a placebo (a fake treatment), and the second 28 weeks where everyone gets the drug.
- Total study time can be up to 80 weeks.
- Participants will have both blinded (unknown treatment) and open-label (known treatment) phases.
- After the study, there’s an option for long-term follow-up or a safety check for 24 weeks.
How understandable was the trial content above?
Hard to understand
Easy to understand